Cyproheptadine as an Appetite Stimulant

S

St. Justine's Hospital

Status and phase

Unknown
Phase 4

Conditions

Failure to Thrive

Treatments

Drug: Cyproheptadine
Drug: Sugar pill

Study type

Interventional

Funder types

Other

Identifiers

NCT01314989
Cypro-24

Details and patient eligibility

About

Cyproheptadine is currently clinically used as an appetite stimulant for children with failure to thrive without underlying organic disease. Otherwise, no randomised control trial demonstrates the efficacy of Cyproheptadine on those patients. This is precisely what the investigators intend to demonstrate on this randomised placebo control cross-over trial. Our hypothesis is that Cyproheptadine is more efficient than placebo to improve weight gain and feeding behaviour on 2 to 4 years old children with failure to thrive.

Enrollment

20 estimated patients

Sex

All

Ages

2 to 4 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 2 to 4 years of age
  • failure to thrive

Exclusion criteria

  • Medication affecting appetite
  • Medication interacting with Cyproheptadine
  • Prematurity under 36 weeks of gestation
  • Neurologic impairment
  • underlying organic disease

Trial design

20 participants in 2 patient groups, including a placebo group

Cyproheptadine
Active Comparator group
Description:
Cross-over study
Treatment:
Drug: Cyproheptadine
Sugar pill
Placebo Comparator group
Description:
Cross-over study
Treatment:
Drug: Sugar pill

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems